Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) LT-Debt-to-Total-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Suzhou Zelgen Biopharmaceuticals Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.01.

Suzhou Zelgen Biopharmaceuticals Co's long-term debt to total assets ratio declined from Mar. 2023 (0.02) to Mar. 2024 (0.01). It may suggest that Suzhou Zelgen Biopharmaceuticals Co is progressively becoming less dependent on debt to grow their business.

Suzhou Zelgen Biopharmaceuticals Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co LT-Debt-to-Total-Asset Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.06

0.01

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.01	0.01	0.01	0.01

Suzhou Zelgen Biopharmaceuticals Co LT-Debt-to-Total-Asset Calculation

Suzhou Zelgen Biopharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	29.456	/	2887.207
	=	0.01

Suzhou Zelgen Biopharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	31.526	/	3104.748
	=	0.01

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Suzhou Zelgen Biopharmaceuticals Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN

Website

http://www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines